{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 4-(5-methoxyheptyl)-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-one
| image = Cioteronel.svg
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = [[Oral administration|Oral]], [[topical administration|topical]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 89672-11-7
| CAS_supplemental = 
| class = [[Nonsteroidal antiandrogen]]
| ATC_prefix = None
| ATC_suffix = 
| PubChem = 55994
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 50555
| ChEMBL = 2104105
| UNII = 1RTH95874Z

<!--Chemical data-->
| C=16 | H=28 | O=2
| molecular_weight = 252.39232 g/mol
| SMILES = CCC(CCCCC1CCC2C1CC(=O)C2)OC
| StdInChI_Ref = 
| StdInChI = InChI=1S/C16H28O2/c1-3-15(18-2)7-5-4-6-12-8-9-13-10-14(17)11-16(12)13/h12-13,15-16H,3-11H2,1-2H3
| StdInChIKey_Ref = 
| StdInChIKey = KDULJHFMZBRAHO-UHFFFAOYSA-N
| synonyms = 
}}

'''Cioteronel''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (developmental code name '''CPC-10997'''; former tentative brand names '''Cyoctol''', '''Ethocyn''', '''X-Andron''') is a [[nonsteroidal antiandrogen]] (NSAA) that was never marketed.<ref name="GanellinTriggle1996">{{cite book|author1=C.R. Ganellin|author2=David J. Triggle|title=Dictionary of Pharmacological Agents|url=https://books.google.com/books?id=Z_mfTTIApVEC&pg=PA570|date=21 November 1996|publisher=CRC Press|isbn=978-0-412-46630-4|pages=570–}}</ref><ref name="Lednicer1994">{{cite book|author=Daniel Lednicer|title=The Organic Chemistry of Drug Synthesis|url=https://books.google.com/books?id=Os_OQxrXYPcC&pg=PA11|date=21 November 1994|publisher=John Wiley & Sons|isbn=978-0-471-58959-4|pages=11–}}</ref><ref name="TiwariKrishna2005">{{cite journal|last1=Tiwari|first1=Atul|last2=Krishna|first2=N S|last3=Nanda|first3=Kamna|last4=Chugh|first4=Anita|title=Benign prostatic hyperplasia: an insight into current investigational medical therapies|journal=Expert Opinion on Investigational Drugs|volume=14|issue=11|year=2005|pages=1359–1372|issn=1354-3784|doi=10.1517/13543784.14.11.1359}}</ref> It was under development between 1989 and 2001 for the [[topical administration|topical]] treatment of [[androgenetic alopecia]] (male pattern baldness) and [[acne]] and for the [[oral administration|oral]] treatment of [[benign prostatic hyperplasia]]; it reached [[Phases of clinical research#Phase III|phase III]] [[clinical trial]]s for acne and [[Phases of clinical research#Phase II|phase II]] studies for androgenetic alopecia, but was ultimately discontinued due to poor [[efficacy]].<ref name="TiwariKrishna2005" /><ref name="AdisInsight">https://adisinsight.springer.com/drugs/800003205{{dead link|date=November 2016 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>

==See also==
* [[Delanterone]]
* [[Inocoterone]]
* [[Metogest]]
* [[Rosterolone]]
* [[Topilutamide]]
* [[Topterone]]
* [[Zanoterone]]

==References==
{{Reflist|2}}

{{Androgenics}}

[[Category:Abandoned drugs]]
[[Category:Anti-acne preparations]]
[[Category:Antiandrogens]]
[[Category:Ketones]]


{{genito-urinary-drug-stub}}
{{dermatologic-drug-stub}}